BPH ENERGY LTD — Investor Presentation 2011

Feb 9, 2011

==> picture [475 x 170] intentionally omitted <==

10 February 2011

Companies Announcements Office Australian Securities Exchange Limited 10[th] Floor, 20 Bond Street SYNDEY NSW 2000

DR. ROBIN SCAIFE TO PRESENT AT THE 4[TH] AUSTRALIAN HIGH CONTENT IMAGE MEETING

BPH Energy Limited [ASX: BPH] is pleased to provide a copy of the presentation that the Principal Researcher Dr. Robin Scaife will present at the 4[th] Australian High Content Image Meeting in Lorne, Melbourne, today.

High Content Imaging has industrialised the field of microscopy, transforming process like fluorescence microscopy from the single glass slide to a fully automated high-throughput imaging process. Since its inception over ten years ago, high-content imaging and analysis has become a pivotal process in early-stage drug discovery. BPH investee company, Molecular Discovery Systems ( MDS ), uses high content imaging and analysis to screen for new oncology drugs.

MDS has gained core expertise in high-content screening and high-throughput imaging and analysis. MDS’ innovative high content imaging and analysis platform detects and quantifies cellular properties much faster than conventional methods, facilitating in the rapid optimisation and prioritisation of drug leads. MDS has effectively utilised high-content imaging and analysis to identify novel cancer drug candidates.

Yours Sincerely,

==> picture [122 x 47] intentionally omitted <==

David Breeze Chairman

==> picture [246 x 95] intentionally omitted <==

==> picture [191 x 105] intentionally omitted <==

• Use of high content imaging and analysis to screen for new oncology drugs Robin Scaife Molecular Discovery Systems WAIMR

==> picture [93 x 51] intentionally omitted <==

Cyclin B Degradation by the UPS

==> picture [654 x 459] intentionally omitted <==

----- Start of picture text ----- CancerTumourcellSpindleCdk1 AssemblyAurora CheckpointPoloCdc20pAnaphasePromotingComplexUbiquitylation ProteasomeCdk1 Cdk1Cyclin B Cyclin BUbAPC/C Ub Metaphase AnaphaseUb----- End of picture text -----

Cell Proliferation shRNA Screen

==> picture [126 x 70] intentionally omitted <==

==> picture [487 x 128] intentionally omitted <==

==> picture [231 x 16] intentionally omitted <==

----- Start of picture text ----- Schlabach et al., Science (2008)----- End of picture text -----

==> picture [686 x 316] intentionally omitted <==

----- Start of picture text ----- Velcade [TM]26SProteasomeUbiquitin----- End of picture text -----

==> picture [104 x 57] intentionally omitted <==

- GFP SUMO Granularity Assay

==> picture [620 x 475] intentionally omitted <==

----- Start of picture text ----- DMSODMSOMG132 MG132High-contentimaging andanalysisPharmacologically DiverseGranularity----- End of picture text -----

==> picture [213 x 18] intentionally omitted <==

----- Start of picture text ----- Pharmacologically Diverse----- End of picture text -----

==> picture [109 x 58] intentionally omitted <==

- - Cyclin B GFP Cell Cycle Screen

==> picture [670 x 426] intentionally omitted <==

----- Start of picture text ----- Courtesy of GE HealtcareBI 6727GFP intensityGFP N/C ratio----- End of picture text -----

==> picture [123 x 67] intentionally omitted <==

Screening of Marine Natural Resources

==> picture [703 x 466] intentionally omitted <==

----- Start of picture text ----- Anti- β -tubulinDMSO MDS-25Paclitaxel40 Vinblastine3530MDS-2525 Taxol201510Cell 50 S5ProliferationS1% mitotic1357911----- End of picture text -----

==> picture [718 x 528] intentionally omitted <==

----- Start of picture text ----- Variation in Response to Mitotic ArrestMitotic FailureMitotic Death 2 [nd] MitosisMitotic DeathTaxol TaxolTime (x1000 min) Time (x1000 min)23h 23.5hGFP-H2B 14.5h 17.5h GFP-H2BMitotic Death Mitotic FailureCells #1-50 Cells #1-50Gascoigne et al., Cancer Cell (2008)----- End of picture text -----

==> picture [138 x 73] intentionally omitted <==

==> picture [223 x 274] intentionally omitted <==

----- Start of picture text ----- Pro-metaphaseTaxol4NMitoticMitoticFailureDeath----- End of picture text -----

Taxol Sensitization

==> picture [461 x 454] intentionally omitted <==

----- Start of picture text ----- Whitehurst et al., Nature (2007)siRNA screenV-ATPaseinhibitionTaxol+RTA203----- End of picture text -----

==> picture [109 x 58] intentionally omitted <==

Induction of Mitotic Death

αPH3 GFP-H2B segmentation segmentation

==> picture [336 x 250] intentionally omitted <==

==> picture [195 x 186] intentionally omitted <==

----- Start of picture text ----- TaxolApoptosis----- End of picture text -----

==> picture [347 x 173] intentionally omitted <==

----- Start of picture text ----- 1.210.80.60.40.205E10Antibody signal----- End of picture text -----

==> picture [265 x 108] intentionally omitted <==

Pharmacologically Diverse

==> picture [109 x 58] intentionally omitted <==

HCS of Mitosis vs Apoptosis

==> picture [702 x 450] intentionally omitted <==

----- Start of picture text ----- GFP-H2BPropidiumPhase GFP-H2BDMSOTsui et al., PLoS (2009)Monopolar spindles:-Small form factor(Area/Perimeter) Taxol-High SD of intensityTX+ DMSOTX+5E10----- End of picture text -----

==> picture [123 x 65] intentionally omitted <==

Inhibition of Mitotic Exit

==> picture [412 x 412] intentionally omitted <==

----- Start of picture text ----- Huang et al., Cancer Cell (2009)SACCdc20TaxolAPC/CsiCDC20Cdk1Manchado et al., Cancer Cell (2010)∆CDC20Apoptosis?----- End of picture text -----

Cyclin-B-GFP

==> picture [202 x 193] intentionally omitted <==

==> picture [203 x 244] intentionally omitted <==

----- Start of picture text ----- Nocodazole (35%M)6h Nocodazole release (4%M)----- End of picture text -----

==> picture [122 x 67] intentionally omitted <==

Selective Inhibition of Proliferation

==> picture [176 x 121] intentionally omitted <==

λ475nm segmentation MCF7 MCF12 λ535nm segmentation

==> picture [156 x 286] intentionally omitted <==

Screening for Selective Growth Inhibition

==> picture [122 x 67] intentionally omitted <==

~50/10,000 compounds

==> picture [656 x 213] intentionally omitted <==

----- Start of picture text ----- ~2/10,000 compoundsNon-selective inhibition Selective inhibitionMCF12 MCF7 MCF12 MCF72000 250020001500t 0 t 015001000 t 48 t 4810005d 6d5005000 0H11 Tx A v e H11 Tx A v e F3 C12 A v e F3 C12 A v eCell # Cell #----- End of picture text -----

==> picture [275 x 14] intentionally omitted <==

----- Start of picture text ----- Selective induction of cell death----- End of picture text -----

==> picture [546 x 175] intentionally omitted <==

==> picture [284 x 151] intentionally omitted <==

Rachel Ramsdale

==> picture [387 x 145] intentionally omitted <==

Jennifer Beaumont Prof. Peter Klinken

==> picture [554 x 84] intentionally omitted <==

Catherine Liptrot

==> picture [290 x 88] intentionally omitted <==